Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients

Saved in:
Bibliographic Details
Published inJournal of Nuclear Medicine Vol. 64; no. 7; pp. 1164 - 1165
Main Authors Seban, Romain-David, Champion, Laurence, Bellesoeur, Audrey, Vincent-Salomon, Anne, Bidard, Francois-Clement
Format Journal Article
LanguageEnglish
Published United States Society of Nuclear Medicine 01.07.2023
Subjects
Biomarkers
Breast cancer
Breast Neoplasms - diagnostic imaging
Breast Neoplasms - drug therapy
Camptothecin
ErbB-2 protein
Female
Humans
Immunoconjugates
Positron-Emission Tomography
Receptor, ErbB-2
Trastuzumab
Trastuzumab - therapeutic use
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0161-5505
1535-5667
2159-662X
DOI:10.2967/jnumed.123.265434